Search
Parkinson's Disease Paid Clinical Trials in Tennessee
A listing of 22 Parkinson's Disease clinical trials in Tennessee actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 22
The state of Tennessee currently has 22 active clinical trials seeking participants for Parkinson's Disease research studies. These trials are conducted in various cities, including Nashville, Memphis, Knoxville and Chattanooga.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Featured Trial
Chronic Kidney Disease (CKD) Clinical Study
Recruiting
A clinical study for people that suffer with Chronic Kidney Disease (CKD)
Conditions:
Chronic Kidney Disease (CKD)
Featured Trial
Ischemic heart disease (IHD) Clinical Study
Recruiting
A clinical study for people that suffer with Ischemic heart disease (IHD)
Conditions:
Ischemic heart disease (IHD)
Corticostriatal Contributions to Parkinson's Disease Cognitive Impairment
Recruiting
The goal of this study is to learn more about the brain activity underlying Parkinson's disease cognitive impairment. The investigators will utilize neural recordings from corticostriatal structures performed during deep brain stimulation surgery to measure neural activity underlying nonmotor symptoms of Parkinson's disease.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/20/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Parkinson Disease
Neurophysiology Biomarkers of Cognitive Impairment Associated With Deep Brain Stimulation
Recruiting
The study aims to investigate cognitive impairment associated with Deep Brain Stimulation (DBS) in Parkinson's Disease patients, with a focus on identifying neurophysiology biomarkers of DBS associated cognitive changes. Using neurophysiology data recorded during DBS surgeries and post-implantation, the research intends to identify biomarkers in order to optimize electrode placement, enhance programming, and ultimately minimize DBS-related cognitive side effects.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/20/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Parkinson Disease
A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Recruiting
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.
Participants will:
• Take NEU-411 or placebo every day for 52 weeks
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
08/18/2025
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Recruiting
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions). Hallucinations or delusions, together called psychosis, occur in u... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/15/2025
Locations: Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee
Conditions: Parkinson's Disease Psychosis
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
Recruiting
Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogeni... Read More
Gender:
ALL
Ages:
Between 35 years and 80 years
Trial Updated:
08/13/2025
Locations: Vanderbilt University Medical Center, 1500 21st Avenue South Suite 2600, Nashville, Tennessee
Conditions: Parkinson Disease
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
Recruiting
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Gender:
ALL
Ages:
Between 45 years and 75 years
Trial Updated:
08/12/2025
Locations: Vanderbilt University (Neurology), Nashville, Tennessee
Conditions: Parkinson Disease
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Recruiting
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.
The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.
Additionally, the utilization of the DBS Illumina 3D feature that may be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Parkinson's Disease
Physiological Brain Atlas Development
Recruiting
The NIH grant has funded the development of a physiological brain atlas registry that will allow us to significantly improve the data collectioin and use of physiological data into a normalized brain volume. This initially was used to improve DBS implants for Parkinson's Disease, Dystonia, Essential Tremor, and OCD, but now includes data acquired during all stereotactic brain procedures.
Gender:
ALL
Ages:
Between 6 years and 90 years
Trial Updated:
08/09/2025
Locations: Vanderbilt Univeristy, Nashville, Tennessee
Conditions: Parkinson's Disease, Obsessive Compulsive Disorder, Dystonia, Essential Tremor, Epilepsy
A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
Recruiting
This trial is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety/tolerability, PK, and pharmacodynamics of VENT 02, administered orally at 1 dose level twice daily (BID) over 28 days in patients with mild to moderate Parkinson's disease.
The study includes a screening period, a 28-day double-blind treatment period, and a 7-day follow-up period after last dose.
Approximately 30 patients will be randomized into 1 of the 2 treatment arms.
Gender:
ALL
Ages:
Between 45 years and 90 years
Trial Updated:
08/06/2025
Locations: Investigative Site, Memphis, Tennessee
Conditions: Parkinson Disease
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Recruiting
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
08/06/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis
Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
Recruiting
This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.
Gender:
ALL
Ages:
Between 50 years and 100 years
Trial Updated:
08/04/2025
Locations: Veracity Neuroscience LLC, Memphis, Tennessee
Conditions: REM Behavior Disorder, Parkinson Disease
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
Recruiting
The purpose of this study is to learn more about the effects of abdominal compression and the medication midodrine, two interventions used for the treatment of orthostatic hypotension (low blood pressure on standing), on hemodynamic markers of cardiovascular risk. The study will be conducted at the Vanderbilt University Medical Center and consists of a screening and 2 testing days, one with abdominal compression and one with midodrine. The total length of the study will be about 5 days.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/31/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Neurogenic Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease
1 - 12 of 22